Form 4: Alumis CDO Mark Bradley Granted Significant Equity Awards

Alumis Inc.'s Chief Development Officer, Mark Christopher Bradley, was granted 26,750 restricted stock units and options to purchase 107,100 shares of common stock, signaling continued executive alignment with company performance.

Summary

• Mark Christopher Bradley, Chief Development Officer of Alumis Inc. (ALMS), was granted 26,750 shares of common stock as Restricted Stock Units (RSUs) on July 29, 2025, with a price of $0.
• The RSU grant vests 25% on August 1, 2026, with the remaining shares vesting in equal quarterly installments over the subsequent 12 quarters, contingent on continuous service.
• Bradley also received options to purchase 107,100 shares of common stock on July 29, 2025, with an exercise price of $3.95 per share.
• The stock options vest 25% on July 29, 2026, and the remaining shares vest in equal monthly installments over the following 36 months, subject to continuous service.
• Following these transactions, Bradley directly beneficially owns 48,728 shares of common stock.
• Additionally, Bradley indirectly beneficially owns 20,026 shares through the JB 2023 GRAT and 20,026 shares through the MB 2023 GRAT, for which he serves as a trustee.
• The filing was signed by Sanam Pangali, Attorney-in-Fact, on July 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a significant equity grant to a key executive, aligning their interests with the company's long-term success. This is a standard and generally well-received practice for incentivizing management.

Positives

• The grant of restricted stock units and stock options to the Chief Development Officer aligns executive incentives with long-term company performance and shareholder value.
• The significant number of shares and options granted indicates a commitment to retaining key management personnel.

Risks

• The vesting of RSUs and stock options is subject to the Reporting Person's Continuous Service, meaning forfeiture could occur if employment ceases before vesting dates.
• The value of the stock options is dependent on the future market price of Alumis Inc. common stock exceeding the exercise price of $3.95.

Future Outlook

The equity grants are structured with future vesting dates extending several years, indicating an expectation of continued service from the Chief Development Officer and a long-term strategic outlook for the company's development initiatives.

Industry Context

Equity grants to key executives are a standard practice in the biotechnology and pharmaceutical industries, particularly for development-stage companies like Alumis Inc., to incentivize long-term commitment and align management interests with shareholder value creation as pipeline assets progress.

Comparison to Industry Standards

• The vesting schedules (25% after one year, then quarterly/monthly over 3-4 years) for both RSUs and stock options are consistent with typical industry standards for executive equity compensation, designed to promote long-term retention and performance.
• The use of both RSUs (which provide value even if the stock price declines) and stock options (which provide upside leverage) is a common diversified approach to executive incentives in biotech, similar to practices at companies like Moderna or BioNTech during their growth phases, aiming to balance risk and reward for executives.

Management Changes

Corporate Governance

Related Party Transactions

• Mark Bradley indirectly beneficially owns shares through the JB 2023 GRAT and MB 2023 GRAT, for which he serves as a trustee. These are related party entities.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Development Officer's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: May signal stability and confidence in the company's future, potentially boosting morale.

Next Steps

• Continued monitoring of Alumis Inc.'s stock performance relative to the option exercise price of $3.95.
• Observation of future Form 4 filings for additional insider transactions by Mark Bradley or other executives.

Key Dates

Recommendation

The filing details a routine executive equity grant, which is a positive signal of management alignment and retention. However, it does not contain new operational or financial performance data that would warrant a change in investment recommendation. It reinforces a 'hold' stance for investors already considering the company, as it indicates standard corporate governance and incentive practices are in place.

Keywords

Alumis Inc., ALMS, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Chief Development Officer, Executive Compensation, Vesting Schedule